Australian patent law requires every invention to qualify as a 'manner of manufacture' under the Statute of Monopolies, yet this centuries-old concept continues to evolve through landmark litigation. The recent Aristocrat v Commissioner of Patents case has reshaped how courts assess computer-implemented inventions, while decisions like D'Arcy v Myriad Genetics have clarified boundaries for biotechnology patents, creating critical implications for businesses evaluating IP portfolios and freedom to operate.
